Repro Medical System Aktie
WKN: 913004 / ISIN: US7599101026
|
13.11.2025 05:07:34
|
After-Hours Gainers: MGNX, SLS, KRMD, HYPR, WVE Post Sharp Moves Following Q3 Updates
(RTTNews) - Several small-cap healthcare and biotech names posted notable price increases in after-hours trading on Wednesday, following earnings updates or ahead of scheduled financial disclosures.
MacroGenics, Inc. (MGNX) rose 10.2% to $1.62 after hours, recovering from a 3.29% decline during the regular session. The company reported third-quarter net income of $16.8 million, or $0.27 per share, down from $56.3 million, or $0.90 per share, in the same quarter last year. Revenue for the period fell to $72.8 million from $110.7 million year-over-year.
SELLAS Life Sciences Group, Inc. (SLS) advanced 9.4% to $1.63 in after-hours trading. The company narrowed its quarterly net loss to $6.8 million, or $0.06 per share, compared to $7.1 million, or $0.10 per share, in the prior-year quarter. As of September 30, 2025, SELLAS reported cash and equivalents of about $44.3 million.
Standard BioTools Inc. (LAB) moved up 4.24% to $1.23 after hours, despite no official press releases or updates on Wednesday. The stock had closed slightly lower during the regular session.
KORU Medical Systems, Inc. (KRMD) gained 8.47% to $4.10 after hours, following a 1.34% increase earlier in the day. The company reported a narrower net loss of $0.8 million for the third quarter, compared to $1.6 million in the prior-year period. Revenue rose 27.2% to $10.4 million. KORU also raised its full-year revenue guidance to a range of $40.5 million - $41.0 million and reaffirmed its gross margin outlook of 61%-63%.
Hyperfine, Inc. (HYPR) climbed 8.18% to $1.19 after hours. No new announcements were made on Wednesday, but the company is scheduled to release its third-quarter results on Thursday. Analysts anticipate a loss of $0.10 per share and revenue of $3.52 million.
Wave Life Sciences Ltd. (WVE) added 5.68% to reach $7.35 in after-hours trading. Earlier in the week, the company reported a third-quarter net loss of $53.9 million, an improvement from $61.8 million in the prior-year quarter. Revenue for the period was $7.6 million, compared to a negative revenue figure of ($7.7) million last year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Macrogenics Incmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Repro Medical System IncShsmehr Analysen
Aktien in diesem Artikel
| Hyperfine Inc Registered Shs | 1,15 | 9,52% |
|
| Macrogenics Inc | 1,30 | -4,92% |
|
| Repro Medical System IncShs | 4,32 | -0,69% |
|
| WAVE Life Sciences Ltd | 6,00 | -4,00% |
|